{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-013704","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2023-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.044578+00:00","generated_at":"2026-06-20T10:53:00.050498+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Verrica resubmits NDA for VP-102 (molluscum contagiosum) to FDA","bullets":["Resubmitted the New Drug Application for VP-102 to the FDA on January 24, 2023.","VP-102 is intended for the treatment of molluscum contagiosum.","No additional details regarding the resubmission content or timeline were disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-013704","json":"https://secwatch.observer/filing/0001193125-23-013704.json","markdown":"https://secwatch.observer/filing/0001193125-23-013704.md","text":"https://secwatch.observer/filing/0001193125-23-013704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523013704/0001193125-23-013704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312523013704/d429269d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T10:53:00.050498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}